Invention Grant
- Patent Title: Treatment of HER-2 dependent cancer using an agent that modulates the activity of a miRNA
-
Application No.: US16758274Application Date: 2018-10-24
-
Publication No.: US11352627B2Publication Date: 2022-06-07
- Inventor: Sandrine Bourdoulous , Anaïs Domingot , Camille Faure
- Applicant: UNIVERSITE DE PARIS , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
- Applicant Address: FR Paris; FR Paris; FR Paris
- Assignee: UNIVERSITE DE PARIS,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
- Current Assignee: UNIVERSITE DE PARIS,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
- Current Assignee Address: FR Paris; FR Paris; FR Paris
- Agency: MH2 Technology Law Group LLP
- Priority: EP17306463 20171024
- International Application: PCT/EP2018/079212 WO 20181024
- International Announcement: WO2019/081607 WO 20190502
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12Q1/68
Abstract:
This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.
Public/Granted literature
- US20200339986A1 TREATMENT OF HER-2 DEPENDENT CANCER USING AN AGENT THAT MODULATES THE ACTIVITY OF A MIRNA Public/Granted day:2020-10-29
Information query
IPC分类:
